) The Laboratory Animal Shared Core Resource continues to provide animal services to Cancer Center members at discounted rates. In addition to services previously provided we have added a treatment and tumor assessment service. The transgenic animal production services which were previously included in this core are now provided and described in the Transgenic/Knockout core. The Laboratory Animal core began operation in 1987, now consists of the original laboratory animal components plus the new animal model tumor testing and intervention service. The core presently serves the research animal needs of 88 Cancer Center investigators including 74 who utilize full core services in the Center for Laboratory Animal Care on the UCHSC campus. The overall objective of the core is to facilitate cancer research and provide Cancer Center investigators with high quality, centralized and specialized services for animal experimentation at reduced and cost effective prices. This shared resource provides routine and specialized maintenance of conventional and barrier- sustained, specific-pathogen-free (SPF) rodents, conventional laboratory animals and transgenic/knockout rodents as well as severe combined immunodeficient (SCID) and athymic, nude mice and rats for allo- and xenografts of tumors and tumor testing, growth and intervention studies. New therapies may be delivered by intravenous, intraperitoneal, transtracheal, intratumoral, intragenic or other routes. Samples for pharmacokinetic analysis are collected for evaluation in the Pharmacology core. The Laboratory Animal core also provides monoclonal and polyclonal antibody production services, gross and histopathology, medical photography and photo microscopy , tumor harvests and transfers, animal model development, preparations and manipulations, training in animal research techniques and laboratory animal veterinary services. The primary goal is to provide state of the art, high quality animal maintenance and research services to Cancer Center investigators that are affordable and accessible.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-15S1
Application #
6664426
Study Section
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Radakovich, Lauren B; Marolf, Angela J; Shannon, John P et al. (2018) Development of a microcomputed tomography scoring system to characterize disease progression in the Hartley guinea pig model of spontaneous osteoarthritis. Connect Tissue Res 59:523-533
Wu, Xiaorong; An, Xiuxiang; Zhang, Caiguo et al. (2018) Clb6-Cdc28 Promotes Ribonucleotide Reductase Subcellular Redistribution during S Phase. Mol Cell Biol 38:

Showing the most recent 10 out of 1634 publications